Could a Low-Calorie diet and Weight-Loss drug send type 2 diabetes into remission?

NCT ID NCT07753447

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a 12-week calorie-restricted diet, combined with the weight-management drug Contrave, can help people with type 2 diabetes and obesity achieve remission. Remission means blood sugar levels drop below the diabetes threshold without needing glucose-lowering medications. The study enrolls adults under 60 who have had diabetes for less than six years and a BMI of 27 or higher. Participants will receive either the dietary intervention with Contrave or a control, and researchers will compare remission rates and weight changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of a low-calorie meal plan and an extended-release medication called Contrave (naltrexone and bupropion) to reduce appetite and support weight loss.
What this could lead to
If successful, this approach could offer a non-surgical path to diabetes remission for people with obesity, potentially reducing or eliminating the need for diabetes medications.
What could go wrong
The trial is small (25 participants) and short (12 weeks), so results may not be generalizable. Remission may not be durable, and the medication can have side effects like nausea, headache, or increased blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yeouido Saint Mary's Hospital

    Seoul, 07345, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.